These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409 [TBL] [Abstract][Full Text] [Related]
3. Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Ricke DO Front Immunol; 2021; 12():640093. PubMed ID: 33717193 [TBL] [Abstract][Full Text] [Related]
4. Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models. Li D; Luan N; Li J; Zhao H; Zhang Y; Long R; Jiang G; Fan S; Xu X; Cao H; Wang Y; Liao Y; Wang L; Liu L; Liu C; Li Q Emerg Microbes Infect; 2021 Dec; 10(1):2194-2198. PubMed ID: 34736354 [TBL] [Abstract][Full Text] [Related]
5. Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development. Bigay J; Le Grand R; Martinon F; Maisonnasse P Front Microbiol; 2022; 13():932408. PubMed ID: 36033843 [TBL] [Abstract][Full Text] [Related]
7. Development of virus-like particles-based vaccines against coronaviruses. Yong CY; Liew WPP; Ong HK; Poh CL Biotechnol Prog; 2022 Nov; 38(6):e3292. PubMed ID: 35932092 [TBL] [Abstract][Full Text] [Related]
8. Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection Luan N; Li T; Wang Y; Cao H; Yin X; Lin K; Liu C Front Immunol; 2022; 13():882856. PubMed ID: 35464483 [TBL] [Abstract][Full Text] [Related]
9. Human and novel coronavirus infections in children: a review. Rajapakse N; Dixit D Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199 [TBL] [Abstract][Full Text] [Related]
11. Coronavirus vaccine development: from SARS and MERS to COVID-19. Li YD; Chi WY; Su JH; Ferrall L; Hung CF; Wu TC J Biomed Sci; 2020 Dec; 27(1):104. PubMed ID: 33341119 [TBL] [Abstract][Full Text] [Related]
12. No Evidence for Human Monocyte-Derived Macrophage Infection and Antibody-Mediated Enhancement of SARS-CoV-2 Infection. García-Nicolás O; V'kovski P; Zettl F; Zimmer G; Thiel V; Summerfield A Front Cell Infect Microbiol; 2021; 11():644574. PubMed ID: 33912475 [TBL] [Abstract][Full Text] [Related]
13. COVID-19 Vaccines: Should We Fear ADE? Halstead SB; Katzelnick L J Infect Dis; 2020 Nov; 222(12):1946-1950. PubMed ID: 32785649 [TBL] [Abstract][Full Text] [Related]
14. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Dai L; Zheng T; Xu K; Han Y; Xu L; Huang E; An Y; Cheng Y; Li S; Liu M; Yang M; Li Y; Cheng H; Yuan Y; Zhang W; Ke C; Wong G; Qi J; Qin C; Yan J; Gao GF Cell; 2020 Aug; 182(3):722-733.e11. PubMed ID: 32645327 [TBL] [Abstract][Full Text] [Related]
15. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients. Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511 [TBL] [Abstract][Full Text] [Related]
16. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P Cells; 2021 Oct; 10(11):. PubMed ID: 34831172 [TBL] [Abstract][Full Text] [Related]
17. Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress. Kovalenko A; Ryabchevskaya E; Evtushenko E; Nikitin N; Karpova O Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675218 [TBL] [Abstract][Full Text] [Related]
19. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
20. The COVID-19 Vaccine Landscape. Koch T; Fathi A; Addo MM Adv Exp Med Biol; 2021; 1318():549-573. PubMed ID: 33973199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]